Key GlaxoSmithKline plc Financials
| Company Type | Public -(London: GSK) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2001 Sales (mil.) | $29,746.0 |
| 2010 Employees | 96,500 |
GlaxoSmithKline plc Stock Quote (NYSE: GSK)(London: GSK)
| Latest 02/15/12 16:00:54 EST | Change ($) | Change (%) | High | Low |
|---|---|---|---|---|
| $44.48 | 0.000 | 0.000 | $0.00 | $0.00 |
Quotes delayed 15 minutes for NASDAQ, 20 minues for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions. |
GlaxoSmithKline plc Income Statement
| Dec 01 | Dec 00 | Dec 99 | |
| Revenue | 29,746.0 | 27,011.9 | 13,758.9 |
| Cost of Goods Sold | 6,431.5 | 4,821.4 | 2,476.3 |
| Gross Profit | 23,314.4 | 22,190.5 | 11,282.6 |
| Gross Profit Margin | 78.4% | 82.2% | 82% |
| SG&A Expense | 10,817.3 | 10,662.1 | 4,847.3 |
| Depreciation & Amortization | 1,177.4 | 1,097.2 | 598.0 |
| Operating Income | 8,841.2 | 7,065.8 | -- |
| Operating Margin | 29.7% | 26.2% | --% |
| Nonoperating Income | 296.1 | 2,804.9 | 478.1 |
| Nonoperating Expenses | -- | -- | -- |
| Income Before Taxes | -- | -- | -- |
| Income Taxes | 2,390.8 | 2,538.1 | 1,209.0 |
| Net Income After Taxes | (2,390.8) | (2,538.1) | (1,209.0) |
| Continuing Operations | 6,424.6 | 6,290.3 | 2,934.9 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 6,424.6 | 6,290.3 | 2,934.9 |
| Total Net Income | 4,490.4 | 6,290.3 | 2,934.9 |
| Net Profit Margin | 15.1% | 23.3% | 21.3% |
| Diluted EPS from Total Net Income | 1.45 | 2.02 | 1.61 |
| Dividends per Share | 0.78 | 1.87 | -- |
All amounts in millions of US Dollars except per share amounts.
GlaxoSmithKline plc Balance Sheet
| Assets | Dec 01 | Dec 00 | Dec 99 |
| Current Assets | |||
| Cash | 1,039.9 | 1,916.6 | 351.6 |
| Net Receivables | 6,566.1 | 6,442.2 | 4,176.3 |
| Inventories | 3,033.8 | 3,402.5 | 2,490.9 |
| Other Current Assets | 3,874.3 | 5,074.2 | 2,834.5 |
| Total Current Assets | 14,514.1 | 16,835.5 | 9,853.3 |
| Net Fixed Assets | 9,937.9 | 9,923.6 | 6,028.7 |
| Other Noncurrent Assets | 7,367.7 | 5,497.9 | 1,016.0 |
| Total Assets | 31,819.7 | 32,257.1 | 16,898.0 |
| Liabilities | Dec 01 | Dec 00 | Dec 99 |
| Current Liabilities | |||
| Accounts Payable | 1,103.7 | 1,213.1 | 594.8 |
| Short-Term Debt | 3,083.7 | 3,408.5 | -- |
| Other Current Liabilities | 9,503.2 | 8,950.4 | 7,934.5 |
| Total Current Liabilities | 13,690.6 | 13,571.9 | 8,529.3 |
| Long-Term Debt | 3,060.7 | 2,616.1 | -- |
| Other Noncurrent Liabilities | 4,155.4 | 4,548.6 | 3,276.8 |
| Total Liabilities | 20,906.7 | 20,736.6 | 11,806.1 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 10,913.0 | 11,520.4 | 5,091.9 |
| Total Equity | 10,913.0 | 11,520.4 | 5,091.9 |
| Shares Outstanding (thou.) | 3,086,483.0 | -- | 2,830,658.1 |
All amounts in millions of US Dollars except per share amounts.
GlaxoSmithKline plc Cash Flow Statement
| Dec 01 | Dec 00 | Dec 99 | |
| Net Operating Cash Flow | 6,677 | 5,797 | 3,005 |
| Net Investing Cash Flow | (3,536.3) | (389.7) | (764.9) |
| Net Financing Cash Flow | (4,028.8) | (4,178.9) | (2,298.0) |
| Net Change in Cash | (888.3) | 1,228.1 | (58.4) |
| Depreciation & Amortization | 1,177.4 | 1,097.2 | 598.0 |
| Capital Expenditures | (1,619.1) | (488.6) | (1,080.9) |
| Cash Dividends Paid | (3,375.8) | (3,029.8) | (2,114.9) |
All amounts in millions of US Dollars except per share amounts.